The Clinical Applications of Extended-Release Abuse-Deterrent Opioids

被引:12
作者
Vadivelu, Nalini [1 ]
Schermer, Erika [1 ]
Kodumudi, Gopal [2 ]
Berger, Jack M. [3 ]
机构
[1] Yale Univ, Sch Med, New Haven, CT 06520 USA
[2] Calif North State Univ, Coll Med, Elk Grove, CA USA
[3] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
关键词
CHRONIC NONCANCER PAIN; OROS(R) HYDROMORPHONE; CANCER PAIN; UNITED-STATES; DOUBLE-BLIND; OPEN-LABEL; LONG-TERM; OXYCODONE; NALOXONE; MODERATE;
D O I
10.1007/s40263-016-0357-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Opioids are the mainstay for treatment of acute pain and cancer pain, and also have a role in the treatment of chronic non-malignant pain. There has been, however, a growing public health problem stemming from the misuse of opioid analgesics leading to serious consequences. To deter abuse, new formulations of extended-release opioid analgesics and tamper-resistant opioids have recently been developed. The concept of abuse-deterrent extended-release opioids is relatively new and, although abuse may not be completely prevented, the utilization of such abuse-deterrent extended-release opioids could reduce this risk. Extended-release abuse-deterrent opioids have been found to have important clinical applications in cancer, acute pain, and chronic non-malignant pain for analgesia control with decreased incidence of tampering and abuse. In this review, different extended-release formulations of opioids available for clinical applications are presented with descriptions of the formulations, their physical properties, and the clinical studies performed to provide physicians with a better understanding of their uses.
引用
收藏
页码:637 / 646
页数:10
相关论文
共 63 条
  • [1] Development and impact of prescription opioid abuse deterrent formulation technologies
    Alexander, Louis
    Mannion, Richard O.
    Weingarten, Brianne
    Fanelli, Richard J.
    Stiles, Gary L.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2014, 138 : 1 - 6
  • [2] Argoff Charles, 2015, J Opioid Manag, V11, P417, DOI 10.5055/jom.2015.0291
  • [3] Validity testing of patient objections to acceptance of tamper-resistant opioid formulations
    Argoff, Charles E.
    Stanos, Steven P.
    Wieman, Matthew S.
    [J]. JOURNAL OF PAIN RESEARCH, 2013, 6 : 367 - 373
  • [4] Will Abuse-Deterrent Formulations of Opioid Analgesics Be Successful in Achieving Their Purpose?
    Bannwarth, Bernard
    [J]. DRUGS, 2012, 72 (13) : 1713 - 1723
  • [5] A pilot study of buprenorphine-naloxone combination tablet (Suboxone®) in treatment of opioid dependence
    Bell, J
    Byron, G
    Gibson, A
    Morris, A
    [J]. DRUG AND ALCOHOL REVIEW, 2004, 23 (03) : 311 - 317
  • [6] Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release
    Benedek, Irma H.
    Jobes, Janet
    Xiang, Qinfang
    Fiske, William D.
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2011, 5 : 455 - 463
  • [7] Bertoli E, 2007, J OROFAC PAIN, V21, P107
  • [8] Blondell RD, 2013, AM FAM PHYSICIAN, V87, P766
  • [9] Current Topics in Opioid Therapy for Pain Management: Addressing the Problem of Abuse
    Casty, Frank E.
    Wieman, Matthew S.
    Shusterman, Neil
    [J]. CLINICAL DRUG INVESTIGATION, 2013, 33 (07) : 459 - 468
  • [10] Opioid Pharmacotherapy for Chronic Non-Cancer Pain in the United States: A Research Guideline for Developing an Evidence-Base
    Chapman, C. Richard
    Lipschitz, David L.
    Angst, Martin S.
    Chou, Roger
    Denisco, Richard C.
    Donaldson, Gary W.
    Fine, Perry G.
    Foley, Kathleen M.
    Gallagher, Rollin M.
    Gilson, Aaron M.
    Haddox, J. David
    Horn, Susan D.
    Inturrisi, Charles E.
    Jick, Susan S.
    Lipman, Arthur G.
    Loeser, John D.
    Noble, Meredith
    Porter, Linda
    Rowbotham, Michael C.
    Schoelles, Karen M.
    Turk, Dennis C.
    Volinn, Ernest
    Von Korff, Michael R.
    Webster, Lynn R.
    Weisner, Constance M.
    [J]. JOURNAL OF PAIN, 2010, 11 (09) : 807 - 829